普瑞巴林的药物动力学学科与不同程度的肾功能。

文章的细节

引用

复制到剪贴板

Randinitis EJ, Posvar EL,阿尔维CW Sedman AJ,库克JA, Bockbrader HN

普瑞巴林的药物动力学学科与不同程度的肾功能。

中国新药杂志。2003年3月,43 (3):277 - 83。

PubMed ID

12638396 (在PubMed

]

文摘

本研究的目标是确定单剂量的药物普瑞巴林与不同程度的肾功能主题,确定与间隙之间的关系,估计肌酐清除率(CLcr),并测量普瑞巴林的血液透析对等离子体的影响水平。结果的基础形式建议与剂量方案患者的肾功能下降。38个受试者登记,以确保广泛的肾功能(CLcr < 30 mL / min, n = 8;30 - 50 n = 5;50 - 80 n = 7;80年>,n = 6)。还招收12学科与肾功能损害需要血液透析。每个主题收到50毫克年前两个25毫克胶囊在这个开放与这些相应平行的组织学习。普瑞巴林浓度测量使用之前验证液相色谱测定方法。通过建立noncompartmental方法进行评估与药代动力学参数。所有科目的普瑞巴林迅速吸收。 Total and renal pregabalin clearance were proportional (56% and 58%, respectively) to CLcr. As a result, area under the plasma concentration-time profile (AUC) and terminal elimination half-life (t1/2) values increased with decreasing renal function. Pregabalin dosage adjustment should be considered for patients with CLcr < 60 mL/min. A 50% reduction in pregabalin daily dose is recommended for patients with CLcr between 30 and 60 mL/min compared to those with CLcr > 60 mL/min. Daily doses should be further reduced by approximately 50% for each additional 50% decrease in CLcr. Pregabalin was highly cleared by hemodialysis. Supplemental pregabalin doses may be required for patients on chronic hemodialysis treatment after each hemodialysis treatment to maintain steady-state plasma pregabalin concentrations within desired ranges.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

普瑞巴林